TREA

79350058 - BEXCLEVY

Follow

Information

  • Trademark
  • 79350058
  • Serial Number
    79350058
  • Registration Number
    7369450
  • Filing Date
    August 12, 2022
    2 years ago
  • Registration Date
    April 30, 2024
    9 months ago
  • Transaction Date
    October 28, 2024
    3 months ago
  • Status Date
    April 30, 2024
    9 months ago
  • Published for Opposition Date
    February 13, 2024
    11 months ago
  • Location Date
    April 29, 2024
    9 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    BLAZICH, JOAN
  • Attorney Docket Number
    8104.0074TM
    Attorney Name
    Mark E. Olds
    Law Office Assigned Location Code
    N40
  • Owners
Information
Mark Drawing Code
4
Mark Identification
BEXCLEVY
Case File Statements
  • GS0051: Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancer, namely, pharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spread, bone marrow dysfunction or suppressions, hematological malignancies, and immunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancer, immunosystem related diseases and disorders, bone marrow dysfunction or suppressions, hematological malignancies, and chronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Antigens, namely, tumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical use, namely, biological preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Immunomodulators, namely, pharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicines, namely, pharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology
Case File Event Statements
  • 6/1/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/16/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 9/19/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/23/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 6/1/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/2/2023 - a year ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 7/8/2023 - a year ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 12/29/2023 - a year ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/8/2023 - a year ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 8/1/2023 - a year ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 12/29/2023 - a year ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/29/2023 - a year ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/5/2024 - a year ago
    13 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/24/2024 - a year ago
    16 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 1/24/2024 - a year ago
    14 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/24/2024 - a year ago
    15 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 2/13/2024 - 11 months ago
    17 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/21/2024 - 11 months ago
    20 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 3/11/2024 - 10 months ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 2/13/2024 - 11 months ago
    18 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/14/2024 - 11 months ago
    19 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 2/21/2024 - 11 months ago
    21 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 4/30/2024 - 9 months ago
    25 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 4/30/2024 - 9 months ago
    23 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 4/30/2024 - 9 months ago
    24 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 7/30/2024 - 6 months ago
    26 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 10/26/2024 - 3 months ago
    27 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 10/27/2024 - 3 months ago
    28 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS